

1 THERAPEUTIC RESPONSE OF UNANI MEDICINE IN THE

2 3 **ABSTRACT**

4 **Introduction:**

5 In men, the Inability to achieve or maintain an erection sufficient for satisfactory sexual
6 function is known as Erectile Dysfunction (ED). It is a common condition affecting
7 approximately 1 in 5 men over the age of 40. Moreover, it is a treatable condition that can
8 significantly impact the well-being of men and their partners. The common causes of this
9 condition are mainly associated with the impairment of vascular and neurological
10 components of the human body. Men who have a problem with their sexual performance may
11 be reluctant to talk to their doctor, seeing it as an embarrassing issue. However, modern
12 medicine has revealed numerous medical and psychological explanations for erectile
13 dysfunction, including the possibility of serious underlying conditions. It is important to
14 address the line of treatment to give the strength to vital organs along with *muqawwiebah*,
15 *muqawwi e Asaab*, and *muqawwi e Aza e Ra'eesa* drugs, which are available in Unani
16 medicine.

17 **Aim and Objectives:**

18 The study aimed to provide holistic relief to participants suffering from Erectile Dysfunction
19 and to provide affordable, natural, and safe medicine for all socio-economic statuses.

20 **Material and Method:** The study was designed as a case control study with a
21 randomized single-blind with a sample size of 40 participants who were randomly
22 allotted into two groups, A & B, with 20 participants in each. The drugs selected for the study
23 in group A are *AqarQarha*, *Tukm e Pyaz*, *Tukm e Sarwali*, *Mochras*, *Alsee*, and *Zanjabeel*.
24 These Unani drugs were given in *suffof* (powder) form orally with a dosage of 5gms morning
25 and evening after food with milk. The drugs selected for the study in group B were *Jarjeer*
26 (*Taramira*), *Naaspal (Post-Anar)*, and *AqarQarha*. The duration of the treatment in both
27 groups is 90 days. All the results were analyzed according to the relevant statistical test.

28 **Results and Discussion:** During the study, group A cases showed 70 % excellent response
29 and 30% showed good response, whereas in group B cases, 30% were noted with Excellent
30 response 50% with good response, and 20% is Satisfactory response. During the study the
31 semen analysis of group A cases revealed that before treatment almost all the cases found
32 with less sperm count, quantity and non-motility of sperms, Decrease Erection, and after the
33 treatment almost 70 % Excellent response and 30 % has shown Good response and whereas
34 the group B cases were noted with Decrease Erection, and after the compilation of treatment
35 cases 30 % were noted with Excellent response and 50% with Good response and 20% is
36 Satisfactory response.

37 **Conclusion:** On the basis of the above result and discussion, it can be concluded that the
38 drugs of Groups A and B produced a significant effect in the treatment of erectile
39 dysfunction. However, the biological mechanisms through which the Group A and B drugs
40 reduce the clinical features still remain unclear and need to be validated with experimental
41 and clinical studies.

42 **Key words:** Unani, Erectile Dysfunction, Zoaf e Istadgi, AqarQarha, Tila.

43 **Introduction**

44 Infertility is the condition when conception does not take place even after one year of regular
45 unprotected sexual intercourse. Approximately 10-25% of couples of reproductive age meet
46 this definition of infertility. Our old physicians say that only 12-25% males are responsible for
47 sterility, but the modern physicians say both are equally responsible for sterility. Erectile
48 Dysfunction is the inability to achieve or maintain an erection or intercourse, difficult or
49 impossible. Erectile Dysfunction is defined as the consistent inability to attain or maintain a
50 sufficiently rigid penile erection for sexual performance.

51
52 The inability to get and keep an erection is known as erectile dysfunction. Lack of libido may
53 occur in conjunction with or apart from it. A number of factors can contribute to ED, which
54 might be psychological, neurogenic, vascular, endocrine, or drug-related [1]. Erectile
55 Dysfunction is inability to recurrent inability to achieve an erection, the inability to maintain
56 an adequate erection. The common causes of ED are reduced libido: hypogonadism,
57 depression, and, with intact libido, psychological problems including anxiety, vascular
58 insufficiency, neuropathic causes, and drugs [2].

59
60 It may occur together or separately with a lack of libido. The most common causes of Erectile
61 Dysfunction are vascular, neuropathic, and psychological. This is a problem with sexual
62 arousal. ED can be defined as the difficulty in achieving or maintaining an erection sufficient
63 for sexual activity or penetration, at least 50% of the time, for a period of six months. It
64 results in significant psychological, social, and physical morbidity and annihilates his essence
65 of masculinity[3].

66
67 According to the WHO, Erectile Dysfunction is a common medical problem affecting
68 approximately 15% of men each year. Over 150 million men worldwide were estimated to
69 have been affected by erectile dysfunction. Erectile Dysfunction may have a physiological or
70 psychological basis, but the most common cause is thought to be related to vascular
71 abnormalities of the penile blood supply and erectile tissue, often associated with
72 cardiovascular diseases and their risk factors [4].

73
74 Unani medicine has a holistic approach towards the diagnosis and treatment of sexual
75 dysfunction that is not just confined to inability to perform sex, rather includes loss of libido,
76 erectile dysfunction, ejaculatory insufficiency, an orgasmic state, excessive nocturnal
77 emissions, and even infertility in males, which may be due to *Zofe Bah* (sexual dysfunction)
78 or *Nuqse Mani* (seminal defects). It also distinguishes between sexual inadequacy and
79 seminal inadequacy [5,6,7].

80
81 According to the Unani system of medicine, health is a state of the body in which there is
82 equilibrium in humors and functions of the body. To maintain the correct humoral balance,
83 there is a power of self-preservation called “*QuwwateMudabbire Badan*” (Immunity of body)
84 in the body. Therefore, the Unani physician aims to find out the cause of the underlying
85 disruption of humors, so that it can be corrected and the disease can be cured.

86
87 The erectile function in a normal person is only possible when the definition of a sound mind
88 in a sound body is fulfilled. There are two basic criteria to be fulfilled while dealing with the

89 physiology of sexual activity. A sound mind takes dominance over the sound body,
90 maintaining the sexual function. The ancient Unani physicians recognized the importance of
91 a sound mind in sexual activity. This leads to the conceptual differentiation of sexual debility
92 (Zoafabah) into two groups. *ZoafeBah Asli*, also called *ZoafeBahHaqeeqi*, *ZoafeBah Shirki*,
93 also called *ZoafeBahGair Haqeeqi*. *ZoafeBah Asli* or *Zoafabah Haqeeqi*: In *ZoafeBah Asli*,
94 the sexual debility is due to dysfunction in the organs of sex, which makes an increasing
95 circulatory deficiency of the penis, resulting in loss of blood supply to the organ or some
96 local disease in the organ. Congenital deformities like Hypospadias, Short penis, stricture, and
97 elongated frenulum penis result in defects in the erection of the penis [5,6,7].

98
99 *ZoafeBah Shirki* or *Zoafabah GairHaqeeqi*: In this category, the sexual organs are well
100 developed, no local disease or disorder in the organs, but the sexual debility is affected due to
101 disease of other organs, e.g., Heart, brain, liver, blood disorder, etc. Psychological
102 derangement affects the sound of mind, resulting in defects in sexual activity. It is the basic
103 principle of Unani medicine regarding sexual disorders that the physiological variations, such
104 as stress, depression, happiness, etc., affect sexual activity.

105
106 This is a problem with sexual arousal. ED can be defined as the difficulty in achieving or
107 maintaining an erection sufficient for sexual activity or penetration, at least 50% of the time,
108 for a period of six months. It results in significant psychological, social, and physical
109 morbidity and annihilates his essence of masculinity [3].

110

111 **Material and Methods**

112 The study was designed as a Randomized Single-Blind comparative clinical trial, and the
113 sample size was determined as 40 participants. After obtaining clearance from the
114 institutional ethical committee, "Therapeutic Response of Unani Medicine in the
115 Management of *Zaof e Istadgi (Nauooz)* (Erectile Dysfunction)" was carried out at the Govt.
116 Nizamia Tibbi College and Hospital, Charminar, Hyderabad, during 2016-2019, and the
117 participants with *Zaof e Istadgi (Nauooz)* (Erectile Dysfunction) were selected from Out
118 Outpatient Department based on clinical signs and symptoms, history, clinical examination,
119 routine investigations (CBP, CUE, RBS, Semen Analysis, Sr. Testosterone), and randomly
120 divided into two Groups A and Group B. After taking their informed consent, they were
121 included in the trial. Participants who fulfill inclusion criteria such as Male age 30 to 55 years
122 of age, Participants with the sense of dejection and shyness, Fear psychosis, Weakness of the
123 nerves, Reduced sperm count, Diabetic mellitus were included in the study and who didn't
124 fulfill inclusion criteria such as suffering from systemic and dreadful diseases, Congenital
125 disorder related with reproductive system, Suffering from venereal diseases, CAD, Age
126 below 30 and above 55 years, Genetic defects, Accessory sex gland infection, Hypertension,
127 and mentally challenged participants were excluded from the study.

128 The duration of treatment was 90 days. All follow-ups were done once every two weeks. The
129 subjective (Trouble getting Erection, Shyness, Fear and objective (Sexual Health Inventory
130 for Men (SHIM), Arbitrary Scoring of the Symptoms) parameters were assessed at each
131 follow-up as 0th day, 15th day, 30th day, 45th day, 60th day, 75th day, and 90th day for the
132 diagnosis and evaluation of the efficacy of the drugs. No concomitant treatment was

133 allowed. The efficacy of treatment of both groups was assessed based on subjective and
 134 objective parameters, the Sexual Health Inventory for Men (SHIM), and the Arbitrary Scoring
 135 of the Symptoms. No concomitant treatment was allowed.

136 List of Ingredients and Method of Preparation of Group - A Formula (*Safoof*);

S. No	Unani Name	English Name	Scientific Name	Quantity
1	<i>AqarQarha</i>	Spanish Pellitory / Spanish Chamomile	<i>Anacyclus pyrethrum</i> DC.	800 mg
2	<i>Tukm e Pyaz</i>	Onion	<i>Allium cepa</i>	1000mg
3	<i>Tukm e Sarwali</i>	French marigold	<i>Tagetescatula</i>	800 mg
4	<i>Mochras</i>	silk-cotton	<i>Bombax ceiba</i> Linn.	800 mg
5	<i>Alsee</i>	Linseed	<i>Linum usitatissimum</i>	800 mg
6	<i>Zanjabeel</i>	Ginger	<i>Zingiber officinalis</i>	800 mg

137
 138 The above drugs were cleaned by weeding out unwanted material and impurities. Then all the
 139 ingredients were powdered and packed in sachets weighing 5 g each. 5 gm twice a day with
 140 milk after meals was given orally to the participants for 90 days.

141
 142 List of Ingredients and Method of Preparation of Group-B Formula.

S. No	Unani Name	English Name	Scientific Name	Quantity
1	<i>Jarjeer (Taramira)</i>	Eruca/Arugula	<i>Eruca sativa</i> Linn.	125mg
2	<i>Naaspal (Post-Anar)</i>	Pomengranate	<i>Punica granatum</i>	1 Tola/10gm
3	<i>AqarQarha</i>	Spanish Pellitory / Spanish Chamomile	<i>Anacyclus pyrethrum</i> DC.	2 Tola/20gm

143
 144 The above drugs were cleaned by removing unwanted materials and impurities. Then they
 145 were mixed and made Tila (Local Application). 2 Ratti of this Tila was locally applied on the
 146 penis completely once a day.

147
 148 **Results**

149 The observations and results concerning demography, clinical symptoms, signs, and SHIM
 150 scores obtained from the trial have been illustrated in tables and graphs. They are discussed in
 151 the following paragraphs consecutively to show the efficacy of the group A and B formulas
 152 separately. As it is evident from Table 1, the highest no of participants observed in the age
 153 group of 35 - 45 years, i.e., 31 cases (77.5%), and the age group. Table 2 shows that the
 154 socio-economic status is a concern for participants from the lower middle class, more than 21
 155 cases (52.5%). In this study, Erectile Dysfunction is more common among skilled
 156 workers with 15 cases (37.5 %), followed by unskilled workers with 11 cases (27.5%), as is
 157 evident in Table 3. As it is evident from Table 4, the highest number of non-vegetarians were
 158 affected, as 38 cases (95%), followed by 02 cases (5%) of vegetarians. In this study, the

159 association of Erectile Dysfunction with diabetes mellitus is evidenced as 28 cases (70%)
 160 were non diabetic, followed by 12 cases (30%) were diabetic participants, as shown in Table 5.
 161 Table 6 shows that the temperament of the participants was assessed based on *Ajnase Ashra*,
 162 and it was recorded that 19 cases (47.5%) were *balghamimizaj* participants, followed by 15
 163 cases (37.5%) were *safravimizaj* participants, whereas 06 cases (15%) were
 164 *sawdav* participants.

165 **Table 1: Incidence in Different Ages**

Age in Years	Group A		Group B	
	No. of Participants	Percentage	No. of Participants	Percentage
30-35	7	35.0	4	20.0
36-40	4	20.0	7	35.0
41-45	4	20.0	5	25.0
46-50	2	10.0	1	5.0
51-55	3	15.0	3	15.0
Total	20	100.0	20	100.0

166

167 **Table 2: Distribution of participants according to Socio-Economic Status**

Socio-Economic Status	Group A		Group B	
	No. of Participants	Percentage	No. of Participants	Percentage
Upper Class (UC)	0	0.0	0	0.0
Upper Middle (UM)	4	20.0	4	20.0
Lower Middle (LM)	11	55.0	10	50.0
Upper Lower (UL)	3	15.0	4	20.0
Lower(L)	2	10.0	2	10.0
Total	20	100.0	20	100.0

168

169

170

171

172

173

174

Table 3: Distribution of participants according to Occupation

Occupation	Group A		Group B	
	No. of Participants	Percentage	No. of Participants	Percentage
Skilled worker	5	25.0	10	50.0
Unskilled worker	4	20.0	7	35.0

Professional	3	15.0	2	10.0
Business man	8	40.0	1	5.0
Total	20	100.0	20	100.0

175
176

Table 4: Distribution According to Diet

Diet	Group A		Group B	
	No. of Participants	Percentage	No. of Participants	Percentage
Non-Veg	18	90.0	20	100.0
Vegetarian	2	10.0	0	0.0
Total	20	100.0	20	100.0

177
178

Table 5: Distribution According to Diabetes Mellitus

Family History	Group A		Group B	
	No. of Participants	Percentage	No. of Participants	Percentage
Present	5	25.0	7	35.0
Absent	15	75.0	13	65.0
Total	20	100.0	20	100.0

179
180

Table 6: Distribution According to Mizaj

Mizaj	Group A		Group B	
	No. of Participants	Percentage	No. of Participants	Percentage
<i>Damavi</i>	0	0.0	0	0.0
<i>Balghami</i>	10	50.0	9	45.0
<i>Safravi</i>	6	30.0	9	45.0
<i>Sawdavi</i>	4	20.0	2	10.0
Total	20	100.0	20	100.0

181
182
183
184
185
186

Table 7: Showing the reduction of symptoms at different follow-ups in Group A and B participants

Parameter	Severity	Base-line	15 th day	30 th day	45 th day	60 th day
Trouble getting an Erection Group A	3+	6	5	-	-	-
	2+	11	11	6	1	-
	1+	3	4	11	6	6

	Absent	-	-	3	13	14
	Total	20	20	20	20	20
Trouble getting an Erection Group B	3+	9	9	3	-	-
	2+	11	9	7	8	4
	1+	-	2	10	6	10
	Absent	-	-	-	6	6
	Total	20	20	20	20	20

187
188

Table 8: Showing remission of the Shim scale after treatment in both Groups

Acc to	Before treatment	After treatment	t-test	p-value
Group-A	12.6 ±4.3	21.9 ±2.9	15.485	<0.00001
Group-B	10.8 ±3.3	19.1 ±3.6	10.751	<0.00001

189
190

Table 9: Showing therapeutic response in Group A and Group B participants

Response	Group-A		Group-B	
	No. of cases	Percentage	No. of cases	Percentage
Excellent	14	70.0	6	30.0
Good response	6	30.0	10	50.0
Satisfactory response	0	0.0	4	20.0
Total	20	100.0	20	100.0

191
192

Discussion

193 As it is evident from Table 1, the highest no of participants observed in the age group of 35 -
194 45 years, i.e., 31 cases (77.5%), and the age group. It shows that the disease is more prevalent
195 in adult persons belonging to this age group. This supports the findings of [8, 9].

196 Table 2 shows that the socio-economic status is a concern for participants from the lower
197 middle class, more than 21 cases (52.5%). According to the above distribution, Erectile
198 Dysfunction may be more prevalent in lower-middle-class males than upper-class males. This
199 supports the findings of [10, 11].
200

201 In this study, Erectile Dysfunction is more common among skilled workers, with 15 cases
202 (37.5 %), followed by unskilled workers with 11 cases (27.5%), as is evident in Table 3. This
203 supports the findings of [12, 13]. As it is evident from Table 4, the highest number of non-
204 vegetarians were affected, as 38 cases (95%), followed by 02 cases (5%) of vegetarians.
205

206 In this study, the association of Erectile Dysfunction with diabetes mellitus is evidenced as 28
207 cases (70%) were non diabetic, followed by 12 cases (30%) were diabetic
208 participants, as shown in Table 5. Men with DM are at a significantly higher risk of ED than
209 those without DM. In line with this, Corona et al. reported a 19.4%, 15.4%, 10.4% and 21.6%

210 prevalence of mild, mild-to-moderate, moderate, and severe ED in men with DM,
211 respectively [14].The severity of ED is highly dependent on the type and duration of DM, the
212 type of treatment, and comorbidities [15, 16, 17].

213


214 A study conducted by Fedele et al. on a large population of men with DM showed a 26% and
215 37% prevalence of ED among those with type 1 DM (T1DM) and type 2 DM (T2DM),
216 respectively.This supports the findings of [18]. Table 6 shows that the temperament of the
217 participants was assessed based on Ajnas-e-Ashra, and it was recorded that 19 cases (47.5%)
218 were *balghamimizaj* participants, followed by 15 cases (37.5%) were
219 *safravimizaj* participants, whereas 06 cases (15%) were *sawdavi* participants. According to the
220 Unani system of medicine, the pathogenesis of most diseases is described in terms of
221 temperament and humour. The diseases of phlegmatic temperament mainly occur in those
222 organs and persons who have having phlegmatic temperament physiologically. With this
223 observation, it can be concluded that subjects with *balghamimizaj* were more prone to have
224 *balghami* ailments like erectile dysfunction. Lack of physical activity was a strong
225 independent risk factor for erectile dysfunction, which most common nature of the *balhgami*
226 individuals. This supports the findings of [19, 20]

227 The efficacy of group A and group B drugs was assessed based on improvements in typical
228 clinical symptoms and signs of obesity. At the end of the study, there were significant
229 improvements in these symptoms in both groups A and B.


230 To assess the results of the study, the data of 40 participants were observed and statistically
231 analyzed. The level of significance was set at 5% ($p = 0.05$), and the differences between the
232 mean Erectile Dysfunction were $p < 0.00001$ and $p < 0.00001$, denote results as highly
233 significant. Whereas $p > 0.05$ denotes results as not significant. The t-test value of erectile
234 function of group A is 15.485, whereas that of group B are respectively 10.751. The graph
235 shows the response of Group A drugs to erectile dysfunction, and their P value is < 0.00001 ,
236 respectively. This shows that the result is significant. The graph shows the response of Group
237 B drugs to erectile dysfunction, and their P value is < 0.00001 , respectively. This shows that
238 the result is significant. No recurrence or exacerbation was reported by any patient after the
239 completion of the trial. No patient reported any adverse events throughout the study or after
240 90 days of follow-up. As the study was done for a limited duration with a small group of
241 participants, further research needs to be carried out in this aspect. Hence, further elaborate
242 studies are awaited in this context with a large sample size for a better drug combination. The
243 therapeutic response of group A showed that out of 20 (100%) participants, 14 (70%) got an
244 excellent response, 06 (30%) got a good response, 0 (0%) got a satisfactory response, and 0
245 (0%) got a poor response. In group B (control), 20 participants, out of whom 06 (30%) got an
246 excellent response, 10 (50%) got a good response, 04 (20%) got a satisfactory response, and 0
247 (0%) got a poor response.

248 It is evident from the above-described observation that Group A medicines are more effective than
249 Group B. Erectile Dysfunction improved in both groups. It is concluded that the efficacy of
250 both Unani formulations on Erectile Dysfunction was found clinically and statistically
251 significant; both groups are safe and effective in the management of erectile dysfunction.

252 Based on the above result and discussion, it can be concluded that the drugs of Groups A and
 253 B produced a significant effect in the treatment of erectile dysfunction. However, the
 254 biological mechanisms through which the Group A and B drugs reduce the clinical features
 255 still remain unclear and need to be validated with experimental and clinical studies.



256
 257 **Fig. 1: Showing remission of the Shim scale after treatment in both Groups**
 258



259
 260 **Fig. 2: Comparative distribution of participants according to therapeutic response in both groups**
 261

262 The effectiveness of the ingredients of the group A and B drugs on *Zaof e istadgiwas*
 263 justifiable based on the various studies that support the use ingredients in this study. Unani
 264 medicines have many herbs that can improve the functions of vital organs. The Unani
 265 pharmacotherapy is based on the correction of abnormal *Mizaj* and providing *Quwwat* to the
 266 Reproductive organs to perform their normal function. The following are the actions of drugs
 267 used in the management of Erectile Dysfunction accordingly. *Muqawwi e Bah*,
 268 *MuqawwieJigar*, *Muqawwi e Aza e Raisa*, *Moghalliz e Mani*, and *Muqawwi e Aasab*. The
 269 supportive findings were as follows:

270 Male rats' sexual behavior may be enhanced by the *ZingiberofficinaleRosc.* Extracts,
 271 particularly at higher doses, could have aphrodisiac benefits. This might be because its
 272 bioactive ingredients have an impact on the neurological system or hormone levels [21].The
 273 *ZingiberofficinaleRosc.* Contains two major constituents, gingerol and shaghol, which
 274 suppress the absorption of dietary fat from the intestines and help in the dissolution of excess
 275 fat deposited in the body. Rihana Kamal et. al. stated that these phytochemicals increase the

276 metabolic rate and thus help to “burn off” excessive fat, which also helps to keep the body
277 active and improve Erectile Dysfunction [22].

278 The onion group had the highest serum total testosterone level, the lamotrigine group had the
279 highest malondialdehyde (MDA) level, and both the onion and ginger groups had the highest
280 overall antioxidant capacity ($p < 0.05$) [23]. With a low dosage of 50 mg/kg in albino rats, this
281 study showed that the petroleum extract of *Anacyclus pyrethrum* alters accessory sexual
282 organ weights, sexual behavior, penile erection, and sexual performance [24]. Additional
283 research on *Anacyclus pyrethrum* revealed that it may increase the frequency of penile
284 erections, mounting and intromissions, and latency instances for these processes, all of which
285 may improve an experimental animal's libido [25]. Further, it plays a major role in reducing
286 depression in participants. It also acts as a memory enhancer, and it shows good results in
287 participants with poor memory. *Anacyclus pyrethrum* possesses therapeutic properties like a
288 nervine stimulant, reducing numbness and pain in the body, which helps to improve the
289 clinical signs and symptoms of diseases like Erectile Dysfunction [26].

290 Supplementing with flaxseed may have an impact on sex hormones, according to conflicting
291 studies. Our goal was to conduct a meta-analysis and systematic review of randomized
292 controlled trials (RCTs) that looked into how supplementing with flaxseed affected the sex
293 hormone profile. Up until March 2023, searches were conducted using the Web of Science,
294 Embase, Cochrane Library, PubMed, Scopus, and Google Scholar databases. A random-
295 effects model was used to calculate the standardized mean difference (SMD). Standard
296 procedures were used to report publication bias, heterogeneity, and sensitivity analysis. The
297 updated Cochrane risk-of-bias technique for randomized trials, called RoB 2, was used to
298 assess each study's quality. Results from 10 RCTs showed that follicle-stimulating hormone
299 (FSH) was not significantly changed by flaxseed supplementation. Adult sex hormones were
300 not significantly impacted by flaxseed supplementation. However, because of the small
301 number of included trials, this topic remains unexplored and requires additional research in
302 subsequent RCTs [27].

303 Juice from *Bombax ceiba* Linn. is regarded as a healing and nourishing tonic. The effects of
304 lyophilized root aqueous extract on male albino rat spermatogenesis and sexual behavior
305 were investigated. In vivo evaluation of five parameters was affected by the administration of
306 100 mg Kg⁻¹ body weight of aqueous extract. Serum testosterone level, anabolic effects,
307 epididymal sperm count, seminal fructose level, and sexual behavior analysis in the presence
308 of a female were the criteria assessed. Animals treated with *B. ceiba* extract showed increases
309 in the weight of their bodies and sexual organs. Significant improvements in mount,
310 intromission, and ejaculation frequencies were observed ($P < 0.05$). Serum testosterone levels
311 also rose; however, this difference was not statistically significant ($P > 0.05$). Significant
312 improvements were also seen in the number of epididymal sperm and the seminal fructose
313 concentration. In addition, the penile erection index was higher than that of the animals in the
314 control group. When compared to the control group, the copulatory rate doubled and the
315 hesitation period was dramatically decreased ($P < 0.01$) in the treated animals [28].

316 Young root, a plant component of *Bombax ceiba* L., is used to treat sexual issues. The young
317 root is known as Semalmusli or Semar-kanda. It exhibits action against a variety of sexual
318 issues. It is used to treat impotence, spermatorrhea, and aphrodisia in the traditional medical
319 system. When it comes to sexual stimulation, the plant's juice is used as a nutrient. In the case
320 of oligospermia, the other plant parts, such as the root powder, are employed to boost the
321 motility and sperm count. *Bombax ceiba* L is used to treat Erectile Dysfunction and other
322 impotence-related issues [29].

323 Recent years have seen the publication of a comparatively large number of studies that
324 concentrate on the biological effects of the extract from *Eruca sativa* (ES) leaves on in vitro
325 and in vivo disease models. Analyzing ES's phytochemical components, traditional
326 applications, potential pharmacological effects, and known effects on male reproductive
327 results is the goal of this narrative review. Numerous components with antioxidant qualities,
328 including polyphenols, glucosinolates, flavonoids, and carotenoids, have been found in ES
329 extracts, according to available research. We demonstrate that ES has potential preventative
330 qualities and therapeutic applications based on the chemical and pharmacological features of
331 the aforementioned substances, particularly in the functional abnormalities of the male
332 reproductive system [30].

333 On the other hand, preclinical in vitro and in vivo studies have clearly shown the
334 effectiveness of pomegranates in modulating key biological processes such as inflammation,
335 hypoxia, and oxidative stress that are significant in the pathophysiology of urological
336 diseases. Clinical trials have also provided more evidence in favour of its application in the
337 management of prostate cancer and other illnesses. Here, we conduct a critical analysis of the
338 scientific literature regarding the present and potential applications of pomegranate extracts
339 in the treatment of prostate cancer, benign prostatic hyperplasia, and Erectile Dysfunction
340 [31].

341 Following the trial, participants who took LN18178 reported significant ($P < 0.05$)
342 improvements in their erection hardness (EHS) and IIEF-5 (International Index of Erectile
343 Function-5) scores, as well as significant improvements in their total and domain scores on
344 the Derogatis Interview for Sexual Functioning-Self Reporting Male (DISF-SR-M)
345 questionnaire. Significant gains in the general health survey (GHS) and multi-dimensional
346 fatigue inventory (MFI) ratings were also found through comparative analysis. When
347 compared to a placebo, LN18178 supplementation significantly ($P < 0.05$) improved the
348 hand-grip strength and six-minute walk distance. The subjects' vital signs, urinalysis, and
349 hemato-biochemical indicators were all within normal limits [32].

350 **Conclusion**

351 In the present study, an attempt is made to treat participants with Erectile Dysfunction with
352 oral Unani drugs to evolve an effective Unani treatment. The response to treatment was
353 defined as an excellent response, a good response, a satisfactory response, or a poor response.
354 Therapeutic response of groups A and B showed that out of 40 participants, 20 (50%)
355 participants got an excellent response, 16 (40%) participants got a good response, 04 (10%)
356 participants got a satisfactory response to their clinical symptoms and signs, and no

357 participants were found in the categories of poor response. It is evidenced that the formulae of
358 both groups have effectiveness in relieving clinical symptoms and signs of erectile
359 dysfunction. It is evident from the above-described observations that group A (test)
360 medicines are more effective than group B (control). Erectile Dysfunction signs & symptoms
361 were improved in both groups. At the end of the study, the statistical significance of the result
362 was noted. It was concluded that the efficacy of Unani formulations on Erectile Dysfunction
363 was found clinically and statistically significant; both groups are safe and effective in the
364 management of erectile dysfunction. Based on the above result and discussion, it can be
365 concluded that the drugs of groups A and B produced a significant effect in the treatment of
366 erectile dysfunction. However, the biological mechanisms through which the test group and
367 control group drugs reduced the clinical symptoms and signs remain unclear and need to be
368 validated with experimental and clinical studies. The conclusion of
369 the study found that $p < 0.00001$, which contradicts the null hypothesis and shows significance.
370

371 **Acknowledgement**

372 We express our sincere and deepest gratitude to Professor Dr. Shahzadi Sultana, MD,
373 Principal of the Government. Nizamia Tibbi College for the opportunity, support, cooperation,
374 and encouragement for doing research work on this topic. We are thankful to the librarians of
375 the Central Library, Government. Nizamia Tibbi College, Library of Central Research
376 Institute of Unani Medicine, Erragadda, Hyderabad, Library of Osmania Medical College,
377 Koti, Hyderabad, and Library of National Institute of Indian Medical Research work. We are
378 greatly thankful to all the individuals who consented to participate in this study.
379

380 **Conflicts of Interest**

381 No conflict of interest.
382

383 **References**

- 384 1. Parveen Kumar, Michael Clark, Clinical Medicine, eighth edition, Elsevier Saunders,
385 2012. Pp. 976.
- 386 2. Brain R. Walker, Nicki R. Colledge, Stuart H. Ralston, Davidson's Principles &
387 Practice of Medicine, 21st edition, Churchill Livingstone Elsevier, 2010. Pp. 477 & 478.
- 388 3. Saxena et al, "Erectile Dysfunction, International Journal of Green Pharmacy",
389 Mednow Publication, 2012.
- 390 4. A. Ahmed, 1 A. Alnaama, 2 K. Shams 2 and M. Salem 1, Prevalence and risk factors of
391 Erectile Dysfunction among participants attending primary health care centres in
392 Qatar, Eastern Mediterranean Health Journal, 2011, Vol 17, No. 7, P. 587-592
- 393 5. Abu Bakr md bin Zakriya Razi "Kitabul Havi" vol 10, CCRUM (Urdu Version) PNo: -
394 265, 266, 267, 268.
- 395 6. Alama Alauddin Qureshi, "Ifadae Kabir", Idara e Kitabushifa, P.no: -151, 152, 153.
- 396 7. Allama Najeebuddin Samarkhandi, "Moalijat e Shara e Asbab", (Tarjuma e
397 Kabir Mukamal), Vol 2, Idara e Kitabushifa, p. 83, 86
- 398 8. Elizabeth Selvin, Arthur L. Burnett, Elizabeth A. Platz, Prevalence and Risk Factors
399 for Erectile Dysfunction in the US, The American Journal of Medicine, Vol 120, No
400 2, February 2007, 151-157).

- 401 9. Francesco Pellegrino, Daniel D. Sjoberg, Amy L. Tin, Nicole
402 E. Benfante, Alberto Briganti, Francesco Montorsi, James A. Eastham, John
403 P. Mulhall, Andrew J. Vickers, Relationship Between Age, Comorbidity, and the
404 Prevalence of Erectile Dysfunction, *European Urology Focus*, Volume 9, Issue
405 1, January 2023, 162-167)
- 406 10. Furukawa S, Miyake T, Yoshida O, et al. Association Between Socioeconomic Status
407 and Erectile Dysfunction in Japanese Participants with Ulcerative Colitis: A Cross-
408 Sectional Study. *American Journal of Men's Health*. 2024;18(3).
409 doi:10.1177/15579883241256833.
- 410 11. Macdonald E, Kim J, Paduch DA. PD47-01 Low Socioeconomic Status Is a Risk
411 Factor for Erectile Dysfunction: An Analysis of NHANES Data. *Journal of Urology*
412 [Internet]. 2022 Jan 1 [cited 2025 May 11];207(Supplement 5): e793. Available from:
413 <https://doi.org/10.1097/JU.0000000000002615.01>
- 414 12. Papaefstathiou E, Apostolopoulou A, Papaefstathiou E, Moysidis K, Hatzimouratidis
415 K, Sarafis P. The impact of burnout and occupational stress on sexual function in both
416 male and female individuals: a cross-sectional study. *Int J Impot Res*. 2020
417 Sep;32(5):510-519. Doi: 10.1038/s41443-019-0170-7. Epub 2019 Jun 26. PMID:
418 31243355.
- 419 13. İşik A Aytaç, Andre B Araujo, Catherine B Johannes, Ken P Kleinman, John
420 B McKinlay, Socioeconomic factors and incidence of erectile dysfunction: findings of
421 the longitudinal Massachusetts Male Aging Study, *Social Science & Medicine* Volume
422 51, Issue 5, 1 September 2000, 771-778. [https://doi.org/10.1016/S0277-](https://doi.org/10.1016/S0277-9536(00)00022-8)
423 [9536\(00\)00022-8](https://doi.org/10.1016/S0277-9536(00)00022-8).
- 424 14. Corona G, Giorda CB, Cucinotta D, Guida P, Nada E, Gruppo di studio S-D. Sexual
425 dysfunction at the onset of type 2 diabetes: the interplay of depression, hormonal and
426 cardiovascular factors. *J Sex Med*. 2014;11(8):2065-2073.
- 427 15. Wang X, Yang X, Cai Y, Wang S, Weng W. High prevalence of Erectile Dysfunction
428 in diabetic men with depressive symptoms: a meta-analysis. *J Sex Med*.
429 2018;15(7):935-941.
- 430 16. Fedele D, Coscelli C, Santeusanio F, et al. Erectile Dysfunction in diabetic subjects in
431 Italy. GruppoItaliano Studio Deficit EretileneiDiabetici. *Diabetes Care*.
432 1998;21(11):1973-1977.
- 433 17. Kamenov ZA. A comprehensive review of Erectile Dysfunction in men with diabetes.
434 *Exp Clin Endocrinol Diabetes*. 2015;123(3):141-158.
- 435 18. Dilixiati D, Waili A, Tuerxunmaiti A, Tao L, Zebibula A, Rexiati M. Risk factors
436 for Erectile Dysfunction in diabetes mellitus: a systematic review and meta-analysis.
437 *Front Endocrinol (Lausanne)*. 2024 Apr 4; 15:1368079. Doi:
438 [10.3389/fendo.2024.1368079](https://doi.org/10.3389/fendo.2024.1368079). PMID: 38638136; PMCID: PMC11024441.)
- 439 19. Elizabeth Selvin, Arthur L. Burnett, Elizabeth A. Platz, Prevalence and Risk Factors
440 for Erectile Dysfunction in the US, *The American Journal of Medicine*, Vol 120, No
441 2, February 2007, 151-157).
- 442 20. Bhat, S. A., & Rather, S. A. (2021). Analysis of temperament/mizaj of men with
443 benign prostatic hyperplasia: novel research. *International Journal of Community*
444 *Medicine and Public Health*, 8(12), 5801–5804. [https://doi.org/10.18203/2394-](https://doi.org/10.18203/2394-6040.ijcmph20214568)
445 [6040.ijcmph20214568](https://doi.org/10.18203/2394-6040.ijcmph20214568)).

- 446 21. Swastika Oktavia, Eneng Elda Ernawati, AncaSuryadi Putra, Aphrodisiac Effects of
447 Ethanollic Extract from White Ginger Rhizome (*Zingiberofficinale*Rosc. var.
448 officinarum) on Male Wistar Rats, *JournalSainsdanTeknologi* Volume 13 Number 3,
449 Tahun 2024, pp. 406-414.
- 450 22. Shaik Mohd Azeem, Md Hussain Shaik, ALM Ihsan. Evaluate the Efficacy of Unani
451 Medicine in the Management of Siman e Mufrit (Obesity), *International Journal of*
452 *AYUSH*; 2024: 13 (10); 58-72.
- 453 23. Khaki A, Farnam A, Badie AD, Nikniaz H. Treatment Effects of Onion (*Allium cepa*)
454 and Ginger (*Zingiber officinale*) on Sexual Behavior of Rat after Inducing an
455 Antiepileptic Drug (lamotrigine). *Balkan Med J.* 2012 Sep;29(3):236-42. doi:
456 10.5152/balkanmedj.2012.045. Epub 2012 Sep 1. PMID: 25207007; PMCID:
457 PMC4115837.)
- 458 24. Sharma Vikas, Thakur M, Singh C, Kumar VD. Evaluation of the anabolic,
459 aphrodisiac, and reproductive activity of *Anacyclus pyrethrum* in male rats.
460 *Pharmaceutical science.* 2009; 77:97- 110.
- 461 25. Usmani A, Khushtar M, Arif M, Siddiqui MA, Sing SP, et al. Pharmacognostic and
462 phytopharmacology study of *Anacyclus pyrethrum*: An insight. *Journal of Applied*
463 *Pharmaceutical Science.* 2016; 6(03):144-50.
- 464 26. Md Hussain Shaik¹, MA Faroqui, ALM Ihsan. Therapeutic response of Unani
465 medicine in the management of DaulShalal al Ra'ash(Parkinson's disease),
466 *International Journal of Advances in Pharmacy Medicine Bioallied Sciences,*
467 2022;10(2):37-43.
- 468 27. Musazadeh V, Nazari A, Natami M, Hajhashemy Z, Kazemi KS, Torabi F, Moridpour
469 AH, Vajdi M, Askari G. The effect of flaxseed supplementation on sex hormone
470 profile in adults: a systematic review and meta-analysis. *Front Nutr.* 2023 Oct 20;
471 10:1222584. doi: 10.3389/fnut.2023.1222584. PMID: 37927501; PMCID:
472 PMC10623424.
- 473 28. Bhargava C, Thakur M, Yadav SK. Effect of *Bombax ceiba* L. on spermatogenesis,
474 sexual behaviour and erectile function in male rats. *Andrologia.* 2012 May;44 Suppl
475 1:474-8. doi: 10.1111/j.1439-0272.2011.01210. x.Epub 2011 Aug 1. PMID:
476 21806665.)
- 477 29. Nikita S, Shweta S, A review on ethnomedicinal, phytoconstituents and
478 phytopharmacology of *Bombax ceiba* L, *Journal of Medicinal Plants Studies* 2020;
479 8(4): 218-221.
- 480 30. Grami D, Selmi S, Rtibi K, Sebai H, De Toni L. Emerging Role of *Eruca sativa* Mill.
481 in Male Reproductive Health. *Nutrients.* 2024 Jan 14;16(2):253. doi:
482 10.3390/nu16020253. PMID: 38257145; PMCID: PMC10818603.
- 483 31. Kroeger N, Belldegrun AS, Pantuck AJ. Pomegranate Extracts in the Management of
484 Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data. *Evid*
485 *Based Complement Alternat Med.* 2013; 2013:701434. Doi: 10.1155/2013/701434.
486 Epub 2013 Mar 26.
- 487 32. Manoj Kumar Srivastava¹, Gaurav Singh, Raveendra Ramamurthy Kodur, Amulya
488 Yalamanchi, A Combination of *Punica granatum* Fruit Rind and *Theobroma cacao*
489 Seed Extracts Enhances Sexual Function in Aging Males in a Randomized, Double-

490
491
492

blind, Placebo-controlled Study, International Journal of Medical Sciences 2025;
22(2): 383-397. doi: 10.7150/ijms.99958.

UNDER PEER REVIEW IN IJAR